Niacinamide (Topical, Vitamin B3 amide form)

Niacinamide is the amide form of vitamin B3 (chemically nicotinamide; distinct from nicotinic acid which is the carboxylic- acid form, see the vitamin-b3 entry for the oral context). In topical skincare it is one of the best-evidenced and best- tolerated cosmetic actives — at 2-10% concentrations, typically 5%, it modulates ceramide and free-fatty-acid synthesis (barrier rebuild), reduces melanosome transfer from melanocytes to keratinocytes (pigmentation evening), modulates sebum production, and has anti-inflammatory effects via PGE2 reduction. The trial evidence base is substantial (Bissett 2005 photoaging RCT; Hakozaki 2002 melanosome transfer; subsequent niacinamide-acne and niacinamide-rosacea trials). Niacinamide is the canonical irritation buffer paired with topical retinoids — the rebuilding of stratum corneum lipid lamellae directly counters the retinol- induced trans-epidermal water loss spike during retinization. Pregnancy and breastfeeding are NOT contraindications (unlike retinol). The "niacinamide + vitamin C cannot be used together" framing is a 1960s formulation-chemistry artefact that does not apply to modern formulations or to AM/PM split routines.

Camden Medicals editorial · Last reviewed 6 May 2026 · Next review May 2027

  • Cross-checked against
  • NHS
  • NICE
  • BNF
  • EFSA
  • FSA
Verifera Evidence ReviewCamden’s own editorial review · evidence-graded, verification in progress — graded, not guessed.

Camden's own editorial team graded each health claim below on the strength of the published evidence — trials weighed with Cochrane RoB 2, systematic reviews with AMSTAR 2, under the CEGA method. See the grade beside every condition.

Class
Vitamin
Typical daily dose
Topical concentrations: 2-3% (entry-level / sensitive); 5% (most-evidenced); 10% (high-strength). Application: morning and / or evening, 1-2× daily. No EU Cosmetic Regulation concentration cap.
Top use evidence
Strong
On this page
  1. What it is
  2. At a glance
  3. What people use it for
  4. How it works
  5. Common myths
  6. Common online questions
  7. The official position
  8. Camden's evidence review
  9. Safety, interactions & who should avoid it
  10. How to take it
  11. How to spot quality
  12. Commonly combined with
  13. Related ingredients
  14. Sources

What it is

Niacinamide (also called nicotinamide, vitamin B3 amide) is the amide derivative of nicotinic acid. The two molecules differ by a single -COOH vs -CONH2 functional group; the difference matters substantially for both oral and topical pharmacology. Oral nicotinic acid produces the niacin flush reaction (cutaneous vasodilation via prostaglandin D2 release from skin Langerhans cells); oral and topical niacinamide do not. Camden's vitamin-b3 entry covers the oral pharmacology of both nicotinic acid and nicotinamide, including the historical use of high-dose oral nicotinic acid for hyperlipidaemia.

In topical skincare, niacinamide is sold at 2-10% concentrations across:
- The Ordinary 10% Niacinamide + 1% Zinc — the entry-level UK product that introduced 10% topical niacinamide to mainstream UK skincare.
- 5% niacinamide serums (Paula's Choice 10% boost, Skinceuticals 5%, La Roche-Posay Effaclar Duo+, CeraVe PM, Olay Regenerist) — the most-evidenced concentration.
- 2-3% niacinamide in moisturisers and combination products (CeraVe daily moisturiser, La Roche-Posay Toleriane).

Niacinamide is photostable (unlike retinol, doesn't degrade on light exposure), pH-flexible (works pH 4-7), water-soluble, and well-tolerated across nearly all skin types — the practical features that explain its dominance as the "starter active" of UK consumer skincare.

At a glance

  • UK regulatory tier: cosmetic ingredient. Topical concentrations: 2-10%, most evidence at 5%. No EU Cosmetic Regulation concentration cap (unlike retinol). No pregnancy / breastfeeding contraindication.
  • Distinct from oral vitamin B3 (nicotinic acid / nicotinamide) — see Camden's vitamin-b3 for the oral context. Topical niacinamide does not produce the niacin flush reaction that oral nicotinic acid can.
  • Mechanisms: (1) ceramide + free fatty acid synthesis (stratum corneum barrier rebuild); (2) melanosome transfer inhibition from melanocytes to keratinocytes (pigmentation evening); (3) sebum modulation (mild anti-acne); (4) anti-inflammatory via PGE2 reduction (rosacea, post-inflammatory erythema).
  • Trial evidence: substantial. Bissett 2005 RCT — 5% niacinamide for 12 weeks improved fine lines, hyperpigmentation, red blotchiness, sallowness, and elasticity vs vehicle. Hakozaki 2002 — 2-5% niacinamide reduced melanosome transfer in vitro and pigmentation in vivo.
  • The canonical retinol pairing — niacinamide buffers the retinization period of dryness, redness, flaking, and stinging. Same product, layered, or AM / PM split all work.
  • The "niacinamide + vitamin C → niacin flush" myth: 1960s formulation chemistry showed acidic conversion of nicotinamide to nicotinic acid at high temperatures over hours. Modern formulations and same-routine application do not produce this conversion at clinically meaningful levels. Apply both — together or split — without concern.

What people use it for

  • Adults with oily / combination skin or mild acne

    Niacinamide 5-10% applied 1-2× daily produces modest sebum reduction, smaller-appearing pores, and reduced post-inflammatory erythema in mild-to-moderate acne over 8-12 weeks. UK NICE NG198 acne pathway is fixed-combination topical adapalene+benzoyl peroxide or topical clindamycin+tretinoin / adapalene first-line — niacinamide is a step-up from cosmetic skincare but not the NICE-pathway clinical-treatment standard for moderate-to-severe acne. [3]

    Some evidenceModerate

  • Adults introducing topical retinol for the first time

    Niacinamide 5% applied alongside retinol — same product, layered, or AM / PM split — may help reduce retinization irritation: niacinamide's barrier-support mechanism (reduced transepidermal water loss) plausibly counters retinol's stratum corneum thinning and TEWL spike. Direct trials of niacinamide specifically easing retinoid irritation are limited — the basis is niacinamide's general barrier evidence plus mechanism, not a head-to-head tolerability RCT. Camden's retinol entry covers the retinization period in detail.

    Some evidenceLimited

  • Adults with rosacea or sensitive / reactive skin

    Niacinamide 2-5% is well-tolerated in rosacea-prone skin — anti-inflammatory PGE2-reduction mechanism reduces flushing and post-inflammatory erythema. UK NICE CKS Rosacea pathway is brimonidine, ivermectin, or oral antibiotics depending on subtype — niacinamide is a compatible adjunct, not a primary treatment. [5]

    Some evidenceLimited

  • Adults with hyperpigmentation, melasma, post-inflammatory hyperpigmentation

    Niacinamide 2-5% over 8-12 weeks produces gradual pigmentation evening via melanosome-transfer inhibition. UK NICE / NHS pathway for melasma is sun protection plus prescription tyrosinase inhibitors (hydroquinone — UK POM); niacinamide is a gentler over-the-counter adjunct, often co-formulated with vitamin C topical for mechanism stacking. [2]

    Some evidenceModerate

  • Pregnant or breastfeeding women

    Niacinamide is NOT contraindicated in pregnancy or breastfeeding — unlike retinol. Topical absorption is low and the molecule is identical to dietary vitamin B3. Many "pregnancy-safe" skincare ranges feature niacinamide as the primary active for that reason. [7]

    Some evidenceStrong

How it works

Ceramide and free-fatty-acid synthesis up-regulation. Niacinamide is a precursor for nicotinamide adenine dinucleotide (NAD+) and NADP — coenzymes for over 400 enzymatic reactions. In keratinocytes, NAD+ availability supports fatty-acid synthesis (which feeds ceramide synthesis via serine palmitoyltransferase), cholesterol synthesis, and free-fatty-acid pool maintenance — the three lipid classes of the stratum corneum lipid lamellae. Bissett 2005 documented increased ceramide content and reduced trans-epidermal water loss with 5% niacinamide for 12 weeks. The barrier-rebuild effect is the mechanism that makes niacinamide the canonical retinol-irritation buffer.

Melanosome transfer inhibition. Pigmentation involves three steps: melanin synthesis in melanocytes (the tyrosinase-driven pathway that hydroquinone and azelaic acid target), melanosome transfer from melanocyte dendrites to keratinocytes, and melanosome distribution / persistence in the epidermis. Niacinamide acts at the second step — reducing the rate at which melanosomes are passed from melanocytes to keratinocytes. Hakozaki 2002 documented this in cell-biology models and in human pigmentation trials. The clinical translation: gradual pigmentation evening over 8-12 weeks of consistent use.

Sebum modulation. Niacinamide reduces sebaceous-gland sebum output via mechanisms not fully characterised — possible suppression of glycerol-3-phosphate dehydrogenase or modulation of androgen-receptor signalling in sebocytes. Trial evidence at 2-5% niacinamide for mild-to-moderate acne and sebum-related concerns is supportive but modest.

Anti-inflammatory via PGE2 reduction. Niacinamide inhibits cyclooxygenase-2 (COX-2) and reduces PGE2 production in inflammatory cells. The downstream effect: reduced erythema, less post-inflammatory redness, and modest improvement in rosacea-prone skin. UK NICE CKS Rosacea pathway does not specifically include niacinamide but it is a common adjunct in rosacea-friendly product lines.

DNA repair signalling. Niacinamide supports PARP-1 (poly-ADP-ribose polymerase 1) activity by maintaining NAD+ pools — PARP-1 is a DNA-damage repair enzyme. Topical niacinamide has been studied in actinic-keratosis prevention (oral niacinamide trial Chen 2015 reduced new non-melanoma skin cancer in high-risk patients; topical signal smaller). UK NICE CKS Sunscreen / actinic keratosis pathway does not specifically include niacinamide but mechanistic basis is established.

Common myths

Myth""Niacinamide and vitamin C cannot be used together — they cancel each other out / cause flushing.""

RealityThe myth originates in 1960s formulation chemistry showing acidic conversion of nicotinamide to nicotinic acid (the flushing form) at high temperatures over hours. Modern formulations and same-routine application do not produce meaningful interconversion at room temperature in human time- scales. Multiple modern combination products (Skinceuticals Phloretin CF, Paula''s Choice C-15) include niacinamide and vitamin C in the same bottle. Same-routine application is fine; AM / PM split (vitamin C morning, niacinamide morning and evening, or vice versa) is also fine. The flushing-myth framing is outdated.

Myth""Higher percentage niacinamide is always better.""

RealityTrial-evidence dose-response is shallow above 5%. Bissett 2005 used 5%; subsequent 10% trials show no meaningful additional benefit for most endpoints. Some users experience flushing or irritation at 10% that resolves at 5%. Choose concentration based on tolerance, not the assumption that 10% is better.

Myth""Niacinamide is just vitamin B3 — same as taking a B3 supplement.""

RealityTopical niacinamide and oral vitamin B3 are not interchangeable. Topical niacinamide does not deliver meaningful systemic vitamin B3; oral B3 does not deliver meaningful concentrations to the stratum corneum. Camden''s vitamin-b3 entry covers the oral pharmacology including the niacin-flush reaction (oral nicotinic acid form, not topical). Both forms have value; the contexts are distinct.

Myth""Niacinamide thins the skin / weakens the barrier.""

RealityBackwards. Niacinamide up-regulates ceramide and free-fatty- acid synthesis, strengthening the stratum corneum lipid lamellae and reducing trans-epidermal water loss. The barrier-rebuild effect is the mechanism that makes niacinamide the canonical retinol-irritation buffer — it does the opposite of thinning.

Myth""Niacinamide cures acne.""

RealityNiacinamide modulates sebum and reduces post-inflammatory erythema in mild-to-moderate acne. UK NICE NG198 first-line for acne is fixed-combination prescription topical adapalene+benzoyl peroxide or topical clindamycin+tretinoin / adapalene — niacinamide is a cosmetic-tier adjunct. [3]

Common online questions

Synthesised from the questions UK shoppers most often ask online about Niacinamide (Topical, Vitamin B3 amide form). Each answer is editorial and links to its evidence in the Sources list below.

How long does niacinamide take to work?

Texture improvements (smaller-appearing pores, smoother feel) emerge at 4-8 weeks; pigmentation evening at 8-12 weeks; photoaging-marker improvements at 12+ weeks of consistent daily use. Effects are gradual, not dramatic.

Can I use niacinamide every day?

Yes — niacinamide is one of the best-tolerated topical actives. Twice daily (AM and PM) is fine for most users. Some users experience mild flushing or irritation at 10% that resolves at 5%.

Niacinamide or retinol for acne?

Different mechanisms with different evidence tiers. UK NICE NG198 first-line for acne is prescription topical retinoid + benzoyl peroxide; OTC retinol has trial evidence but is a step-up from cosmetic skincare; niacinamide is a cosmetic- tier adjunct. For mild acne, niacinamide alone is reasonable; for moderate-to-severe acne, NICE pathway via GP. For first- time topical-active users, niacinamide is the gentler starting point. [3]

Can I use niacinamide while pregnant?

Yes — niacinamide is NOT contraindicated in pregnancy or breastfeeding. Topical absorption is low and the molecule is identical to dietary vitamin B3. Many "pregnancy-safe" skincare ranges feature niacinamide as the primary active. For comparison, retinol IS contraindicated in pregnancy. [7]

My skin flushes when I apply 10% niacinamide — what is this?

Some users experience mild facial flushing or warmth at 10% topical niacinamide. The mechanism is uncertain (possibly modest histamine release, possibly contaminating residual nicotinic acid in the formulation). The flushing is harmless and resolves on stopping. Switch to 5% niacinamide — most users tolerate this without flushing.

⚖️ The official position

What may lawfully be claimed about Niacinamide (Topical, Vitamin B3 amide form) in Great Britain. This is a regulatory position, not an evidence grade.

No health claim is authorised for Niacinamide (Topical, Vitamin B3 amide form) in Great Britain.

This page describes the evidence and online discussion without making a claim.

UK regulatory landscape

UK regulatory tier: Food supplement

EFSA claim status

Topical niacinamide is regulated under EU Cosmetic Regulation, NOT under EU Nutrition and Health Claims Regulation 1924/2006. Cosmetic claims (anti-photoaging, pigmentation, sebum control) are governed by cosmetic-claim rules + ASA / CAP advertising codes. Oral B3 carries multiple UK Article 13.1 claims captured in `_shared.yml.gb_nhc_register.vitamin_b3`.

UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.

🔬 Camden’s evidence review

The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.

  1. Photoaging — fine lines, texture, dyspigmentation, elasticity

    Evidencemoderate

    Bissett 2005 (Dermatologic Surgery) RCT in 50 women applied 5% niacinamide for 12 weeks; significant improvements in fine lines, hyperpigmentation, red blotchiness, sallowness, and elasticity vs vehicle control. Subsequent trials and product-RCTs have replicated the photoaging-marker pattern. [8,9,10]

  2. Hyperpigmentation / melasma / post-inflammatory hyperpigmentation

    Evidencemoderate

    Hakozaki 2002 demonstrated niacinamide''s melanosome-transfer- inhibition mechanism in vitro and reduced pigmentation in vivo at 2-5% concentrations over 8-12 weeks. Subsequent Asian-skin trials and Olay / Skinceuticals product trials replicated. Mechanism distinct from tyrosinase inhibitors (hydroquinone, kojic acid) — combination is mechanism-additive. [2]

  3. Acne — sebum control, mild inflammatory acne

    Evidencelimited

    Niacinamide 2-5% has trial evidence for mild-to-moderate inflammatory acne via sebum modulation + anti-inflammatory mechanisms. UK NICE NG198 acne first-line is prescription topical retinoid + benzoyl peroxide — niacinamide is a cosmetic-tier adjunct. [3]

  4. Rosacea — erythema, flushing, post-inflammatory erythema

    Evidencelimited

    Niacinamide''s anti-inflammatory PGE2-reduction mechanism supports rosacea-prone skin tolerance. UK NICE CKS Rosacea pathway does not specifically include niacinamide. [5]

  5. Non-melanoma skin cancer prevention (oral)

    Evidencemoderate

    Chen 2015 (NEJM) — 386 high-risk patients, 500 mg oral nicotinamide twice daily for 12 months reduced new non- melanoma skin cancers by 23%. Effect specific to oral nicotinamide, not topical. UK NICE pathway for actinic keratosis does not currently include nicotinamide supplementation; talk to dermatologist if high-risk. [3]

Safety

Niacinamide is one of the best-tolerated topical actives. Mild flushing at 10% in some users (resolves at 5%). NOT contraindicated in pregnancy / breastfeeding (unlike retinol).

Talk to your pharmacist or GP first if you:

  • You experience flushing on application — switch to 5% niacinamide.
  • You have a known allergy to niacinamide or B3 derivatives — rare but possible.

Common side effects: Mild flushing or warmth at 10% (rare, resolves at 5%). Very rare contact dermatitis.

Pregnancy and breastfeeding

Niacinamide is NOT contraindicated in pregnancy or breastfeeding. Topical absorption is low; molecule is identical to dietary B3.

As pregnancy.

Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.

More clinical detail (for clinicians and informed readers)

Contraindications

  • Hypersensitivity to niacinamide.

Drug interactions

  • No clinically significant topical interactions documented.
  • Theoretical interaction at the same-product co-formulation with high-strength acidic actives (AHA / BHA / ascorbic acid pH<3) — formulation chemistry; modern co-formulations work fine.

This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.

Common side effects

  • Generally well-tolerated.
  • Mild flushing or warmth on application at 10% in some users.

Rare side effects

  • Contact dermatitis (very rare).
  • Mild GI upset from oral B3 supplements (NOT from topical niacinamide; included for myth-correction context only).

How to take it

Typical supplemental range
Topical concentrations: 2-3% (entry-level / sensitive); 5% (most-evidenced); 10% (high-strength). Application: morning and / or evening, 1-2× daily. No EU Cosmetic Regulation concentration cap.
Timing
Morning, evening, or both. Compatible with retinol (canonical pair), vitamin C topical (myth corrected), AHA / BHA, sunscreen.

How to spot quality

Look for

  • Niacinamide percentage clearly stated (2%, 5%, 10%).
  • For combination products: niacinamide + retinol (canonical pair) or niacinamide + zinc (acne pair) or niacinamide + vitamin C (myth-corrected pair).
  • pH 4-7 (niacinamide is pH-flexible; the 1960s flushing-myth framing about pH does not apply to modern formulations).
  • Ceramide content disclosed — niacinamide's mechanism is barrier-rebuild via ceramide synthesis support; products with added ceramides (CeraVe, La Roche-Posay) are mechanism-coherent.
  • GMP-certified manufacture.

Red flags

  • No niacinamide percentage declared.
  • Marketing as age-reversal positioning — triggered by do_not_claim_regex; use "anti-photoaging" or "fine line and texture support".
  • Marketing as a clinical-grade acne remedy — outside UK NICE NG198 pathway.
  • Marketing implying clinical equivalence to prescription retinoids.
  • Combination with kava (banned in UK as a food supplement).

Commonly combined with

Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.

Retinol (Vitamin A1, all-trans-retinol)

Limited evidence

The canonical first-time-retinoid pairing — niacinamide buffers retinization irritation, supports ceramide synthesis, strengthens stratum corneum barrier.

Retinol drives keratinocyte turnover speedup and stratum corneum reorganisation; niacinamide up-regulates ceramide, free-fatty-acid, and cholesterol synthesis to maintain barrier integrity through the retinization period. Mechanism-complementary on the barrier-rebuilding axis.

Bissett 2005 niacinamide-only barrier-function evidence + retinol photoaging trial body support the combination. Many UK products co-formulate (Olay Regenerist Retinol24, Skinceuticals Retinol+Niacinamide). Trial-grade pairing pattern: 5% niacinamide AM + PM, retinol 0.2-0.5% PM only.

Evidence: Mechanism complementary on barrier axis. Combination product RCTs supportive. Bissett 2005 + retinol photoaging trial body foundational. [11,12,13,14]

Doses studied: 5% niacinamide AM and PM + 0.2-0.5% retinol PM (same product, layered, or AM/PM split).

Zinc

Limited evidence

Acne-cluster pairing — The Ordinary 10% Niacinamide + 1% Zinc is the foundational UK product. Zinc adds sebum modulation and modest antibacterial activity to niacinamide's ceramide + anti-inflammatory axes.

Zinc PCA (the cosmetic form in The Ordinary's product) modulates 5-α-reductase activity in sebocytes (reducing dihydrotestosterone-driven sebum) and has modest antibacterial activity against Cutibacterium acnes (the primary acne-associated bacterium). Niacinamide adds separate sebum modulation (mechanism unclear), barrier rebuild via ceramide synthesis, and anti-inflammatory PGE2 reduction.

The combination is mechanism-additive on the acne axis without overlapping. UK NICE NG198 first-line for moderate-to-severe acne is prescription topical retinoid + benzoyl peroxide; the niacinamide-zinc combination is cosmetic-tier adjunct for mild acne.

Evidence: Mechanism complementary across sebum / antibacterial axes. Direct combination trial evidence small; The Ordinary product RCTs supportive at 10% niacinamide + 1% zinc. [3,6]

Doses studied: 10% niacinamide + 1% zinc PCA topical, 1-2× daily.

Vitamin C topical (L-ascorbic acid + ester derivatives)

Limited evidence

Myth-corrected pairing — the 1960s "cancel each other out" framing is outdated. Modern formulations and same-routine or AM/PM split applications work without conflict.

Old paradigm: nicotinamide + ascorbic acid at acidic pH 3 over hours at high temperature partially convert nicotinamide to nicotinic acid (the flush form). Modern paradigm: room-temperature, human-timescale application of niacinamide (5%, pH 5-6) and vitamin C (10-20% L-ascorbic acid pH 3-3.5; or pH-stable esters like THD ascorbate) does not produce meaningful interconversion.

Skinceuticals Phloretin CF, Paula's Choice C-15, and other modern products co-formulate without the historical pH-conflict concern. Same-routine layered application or AM/PM split are both standard practice.

The combination addresses photoaging from two angles: vitamin C antioxidant ROS scavenging (reduces oxidative damage); niacinamide barrier rebuild + melanosome-transfer inhibition + anti-inflammatory. Mechanism-complementary across the photoaging cascade.

Evidence: Mechanism complementary; pH-conflict framing outdated. Combination trials small; each component has its own larger trial body.

Doses studied: 5% niacinamide + 10-20% L-ascorbic acid or 5-15% THD ascorbate, AM (vitamin C) + AM/PM (niacinamide), or co-formulated combination products.

CO2 Laser (Carbon Dioxide Fractional / Ablative Laser Resurfacing)

Limited evidence

Post-procedure barrier-rebuild adjunct.

Niacinamide ceramide / FFA synthesis support compatible with post-CO2 barrier rebuild. Use only after re-epithelialisation complete.

Evidence: Compatible adjunct.

Doses studied: Post-CO2 day 7-14: 5% niacinamide AM + PM.

Isotretinoin (13-cis-retinoic acid; UK POM — Roaccutane, Reticutan)

Limited evidence

During-treatment barrier-rebuild adjunct. Compatible with isotretinoin (unlike topical retinol).

Niacinamide ceramide / FFA synthesis support buffers isotretinoin-induced barrier disruption. Universal compatible during-treatment adjunct.

Evidence: During-treatment compatible adjunct.

Doses studied: AM and PM during isotretinoin course: 5% niacinamide + ceramide moisturiser.

Microneedling (Collagen Induction Therapy / Percutaneous Collagen Induction)

Limited evidence

Post-procedure barrier-rebuild adjunct — niacinamide ceramide / FFA synthesis support compatible immediately post.

Niacinamide barrier-rebuild mechanism compatible with wound-healing cascade. Pregnancy-safe. Use immediately post-procedure.

Evidence: Compatible adjunct immediately post.

Doses studied: Post-procedure: 5% niacinamide AM + PM.

Retinaldehyde (Retinal)

Limited evidence

Marketed as a retinoid-irritation buffer, but the one direct patch-test RCT (Fang 2024) found 3% niacinamide did not relieve retinol-induced irritation — niacinamide's barrier support is general, not a demonstrated retinoid buffer. See Camden niacinamide + retinol.

Niacinamide ceramide / FFA synthesis support buffers retinaldehyde retinization. Mechanism-complementary on barrier-rebuild axis.

Evidence: Same trial body as retinol-niacinamide pairing.

Doses studied: 5% niacinamide AM + PM, retinaldehyde 0.05-0.1% PM only.

Melatonin (Topical, skin-antioxidant context)

Limited evidence

Barrier-rebuild + antioxidant cluster.

Niacinamide ceramide / FFA synthesis + anti-inflammatory; melatonin antioxidant + circadian barrier signalling. Mechanism-complementary on barrier + redox axes.

Evidence: Mechanism complementary; combination trials small.

Doses studied: PM: niacinamide → melatonin → moisturiser.

Vitamin B3 (Niacin / Nicotinamide)

Insufficient evidence

Topical sister entry — niacinamide is the topical-skin form of vitamin B3 amide.

Same molecule (nicotinamide / niacinamide); different delivery context — topical for stratum corneum barrier rebuild + melanosome transfer + sebum modulation. Camden niacinamide covers topical.

Evidence: Camden niacinamide covers topical context.

Doses studied: Oral 16 mg/day NRV. Topical 5-10%.

Related ingredients

Sources

Numbered references cited above plus general authoritative reading. Citations in the body link to the matching number here.

How to read these sources:

  • Tier 1 (UK authoritative): NHS, NICE, BNF, EFSA, FSA, GB NHC Register, SACN, MHRA.
  • Tier 2 (primary literature): peer-reviewed RCTs cited by PMID.
  • Tier 3 (mechanistic): in-vitro / animal-model literature — interpret with caveat.
  1. NHS — Acne
  2. NHS — Rosacea
  3. NICE NG198 — Acne vulgaris management
  4. NICE NG198 — Acne vulgaris: management
  5. NICE CKS — Rosacea
  6. GB Nutrition and Health Claims Register
  7. NHS — pregnancy › keeping well › have a healthy diet
  8. PubMed PMID 16029679
  9. PubMed PMID 25940759
  10. PubMed PMID 34958693
  11. PubMed PMID 17121065
  12. PubMed PMID 10971324
  13. PubMed PMID 36798538
  14. PubMed PMID 38299457

Verifera® is published by Camden Medicals — a UK supplement retailer. We have a commercial interest in some of the ingredients described here; we declare it on every page and our editorial process forbids adjusting copy to favour our own products. Read our editorial policy.

This page is information, not medical advice. Talk to your pharmacist or GP before starting any supplement, especially if you take prescribed medicines, are pregnant or breastfeeding, or have an existing condition.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme: yellowcard.mhra.gov.uk